Facebook icon Twitter icon Forward icon

CGM improves glucose control in type 1 diabetes

The use of continuous glucose monitoring (CGM) leads to a greater decrease in HbA1c levels compared with usual care, according to a new study.

The DIaMonD study (Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes) was the first of its kind as it demonstrated the impact of CGM on HbA1C and hypoglycaemia in adults with type 1 diabetes on a multiple daily injection insulin regimen. To read more, click here

Suliqua approved in Europe for adults with type 2 diabetes

Sanofi’s new insulin and GLP-1 combination Suliqua has received marketing approval from the European Commission.

The once-daily treatment combines Lantus (insulin glargine) with Lyxumia (lixisenatide) and is authorised for use in combination with metformin to improve glycaemic control as a further treatment option. To read more, click here

Green light for new two-drug therapy from AstraZeneca

AstraZeneca’s two-drug therapy for type 2 diabetes Qtern (saxagliptin and dapagliflozin fixed-dose combination) is now available in the UK for adults.

Saxagliptin and dapagliflozin fixed-dose combination (saxa/dapa FDC) is a once-daily tablet that combines saxagliptin 5mg, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with dapagliflozin 10mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

To read more, click here

New safer insulin prescribing summary

NICE has published new advice about prescribing insulin to support improved clinical practice.

The online resource called ‘Safer insulin prescribing’ summarises the evidence base in the therapeutic area to supporting the medicine's optimisationn, but is not formal NICE guidance.

To read more, cllck here.

Long-term benefits of diabetes intervention programme demonstrated

The long-term impact of an intensive lifestyle intervention on cardiovascular risk factors in people with type 2 diabetes has been proven in real-world clinical practice.

Results from a follow-up study of obese people with type 2 diabetes, who lost at least seven per cent of their body weight after one year of an intensive lifestyle intervention, show that those who sustained their weight loss maintained most of its benefits on HbA1c and cholesterol for five years.

To read more, click here.